CABALETTA BIO, INC. Payments to Acquire Debt Securities, Available-for-sale
CABALETTA BIO, INC. (CABA) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-13
- CABALETTA BIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00.
- CABALETTA BIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $50.00M.
- CABALETTA BIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- CABALETTA BIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-09-30 was $0.00.
- CABALETTA BIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $99.04M.
- CABALETTA BIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- CABALETTA BIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $84.26M, a 69.33% increase from fiscal 2022.
- CABALETTA BIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $49.76M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $50.00M derived: sum of 2 quarters · filed 2026-03-23 | $99.04M 10-K · filed 2026-03-23 | |
| 2025-09-30 | $50.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $99.04M 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $49.03M 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 derived: sum of 3 quarters · filed 2026-03-23 | $0.00 10-K · filed 2026-03-23 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | $36.18M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $36.18M derived: sum of 3 quarters · filed 2025-08-07 | $36.18M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $36.18M derived: sum of 2 quarters · filed 2025-03-31 | $36.18M derived: sum of 3 quarters · filed 2025-03-31 | $84.26M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $36.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $36.18M derived: sum of 2 quarters · filed 2025-03-31 | $84.26M derived: sum of 3 quarters · filed 2025-03-31 | $84.26M 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $48.09M derived: sum of 2 quarters · filed 2024-11-14 | $48.09M 10-Q · filed 2024-11-14 | $48.09M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $48.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $48.09M 10-Q · filed 2024-08-08 | $48.09M derived: sum of 3 quarters · filed 2024-08-08 | $48.09M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-15 | $0.00 derived: sum of 2 quarters · filed 2024-05-15 | $0.00 derived: sum of 3 quarters · filed 2024-05-15 | $0.00 derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $0.00 derived: sum of 2 quarters · filed 2024-03-21 | $0.00 derived: sum of 3 quarters · filed 2024-03-21 | $49.76M 10-K · filed 2024-03-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $49.76M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $49.76M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $49.76M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-16 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $11.10M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $11.10M 10-Q · filed 2021-11-01 | ||
| 2020-06-30 | $11.10M 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |